Status:

NOT_YET_RECRUITING

xDRIVE in Metastatic Colorectal Cancer

Lead Sponsor:

First Ascent Biomedical Inc.

Collaborating Sponsors:

Mayo Clinic

Florida International University

Conditions:

Metastatic Colon Adenocarcinoma

Metastatic Colon Cancer

Eligibility:

All Genders

18+ years

Brief Summary

The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (m...

Detailed Description

Metastatic colorectal cancer (mCRC) remains a critical unmet clinical need, necessitating innovative approaches to improve patient outcomes. Functional precision medicine (FPM)-guided interventions of...

Eligibility Criteria

Inclusion

  • Participants (men and women) enrolled in internal review board (IRB) 622-00 and meet the following criteria.
  • Participants ≥18 years of age with a diagnosis of mCRC who are willing to consent to the study
  • Participants with Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2.
  • Participants with measurable disease
  • Participants who need to start SOC cancer-directed systemic therapy
  • Participants able to provide treatment and outcome information from previous lines of therapy.
  • Participants who will need a tumor biopsy, excision, or resection as part of their routine clinical care.
  • Participants willing to have a blood draw performed for matched normal material.
  • Participants who plan to have their first radiographic assessment of their cancer at Mayo Clinic.

Exclusion

  • Participants who do not have malignant tissue available or safely accessible or do not have sufficient amount of tissue from anticipated biopsy, excision or resection for testing.
  • Participants who do not have measurable disease.
  • Participants with insufficient health indicators to undergo therapeutic intervention for mCRC based on treating oncologist's clinical assessment.
  • Participants with other concurrent cancers besides mCRC which also require ongoing cancer-directed therapy.
  • Participants who cannot provide an informed consent.

Key Trial Info

Start Date :

September 15 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 30 2027

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06929338

Start Date

September 15 2025

End Date

June 30 2027

Last Update

September 16 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

xDRIVE in Metastatic Colorectal Cancer | DecenTrialz